Clinical and angiographic outcomes after use of 90Strontium/90Yttrium beta radiation for the treatment of in-stent restenosis: results from the Stents and Radiation Therapy 40 (START 40) registry

Evolution of vascular brachytherapy over time: Data from the RENO-registry analysis

“…This may result in recurrent ISR at the edges of a previously VBT-treated segment of the coronary artery [20 21]. The incidence of geographic miss can be minimised by using longer sourcelength catheters (40 or 60 mm) [22].…”

Long‐term follow‐up of brachytherapy for treatment of allograft in‐stent restenosis

“…The use of ionizing radiation, by reducing neointimal proliferation responsible for in-stent restenosis, has emerged as a novel modality to treat in-stent restenosis in native coronary arteries [17] and vein grafts with encouraging results [18]. The START registry of beta-radiation treatment of native coronary in-stent restenosis showed an 8-months target lesion revascularization rate (TLV) of 15.9% vs. 24.1% in the placebo group (P ϭ 0.03) [17].…”

“…The START registry of beta-radiation treatment of native coronary in-stent restenosis showed an 8-months target lesion revascularization rate (TLV) of 15.9% vs. 24.1% in the placebo group (P ϭ 0.03) [17]. Brachytherapy of vein graft in-stent restenosis showed 21% restenosis rate at 6 months and 70% reduction of TLV at 1 year.…”

Improving patient-specific dosimetry for intravascular brachytherapy

“…The ISR rate drops from 35-45% to well below 15% on using IVBT (1)(2)(3)(4)(5)(6). Long-term follow-up on several ISR IVBT clinical trials has shown that the reduction of restenosis is persistent, and the side effects of this treatment are not serious enough to offset benefits.…”